An observational study in Trigeminal Neuralgia, sponsored by Noema Pharma AG. Completed at 2 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-12-10.
Sponsored by Noema Pharma AG · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Trigeminal Neuralgia with a site in United States — 7 open to participants now, 11 under way, 1 of them phase 3. Trigeminal Neuralgia · United States.
Among the 34 studies in Trigeminal Neuralgia with a site in United States, this one is one of 3 that started in 2021, is one of 8 observational ones, and was the 29th registered.
140 studies on the registry are indexed under Trigeminal Neuralgia; 44 are open to participants now.
Browse Trigeminal Neuralgia studies →7 of the 34 studies in Trigeminal Neuralgia with a site in United States are open now. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 18+
University of Minnesota · Sites in United States
Ages 18+ · Healthy volunteers
The Foundation for Orthopaedics and Regenerative Medicine · Sites in United States, Greece
University of Minnesota · Sites in United States
Ages 18+ · Healthy volunteers
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 27 Trigeminal Neuralgia studies recruiting now, 18 (67%) set no upper age limit and 3 (11%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 40 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 4 · Phase 4 3
First in 1997; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 84 across 38 observational studies indexed under Trigeminal Neuralgia.
Median enrollment 29 across the 26 interventional studies, 56 across the 8 observational. Of the 18 that completed or were terminated, 7 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 34 have an industry lead sponsor. The 10 most frequent:
Noema Pharma AG is the lead sponsor of 6 studies on the registry; none are open to participants now.
Noema Pharma AG has 2 studies filed under Trigeminal Neuralgia — fewer than ten, so there is no comparison to draw.
5 of the studies in Trigeminal Neuralgia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05217628Phase 3Noema Pharma AGAn Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia. | 2027-02-02 |
| NCT05593237University of California, San FranciscoTranscranial Magnetic Stimulation for Chronic Neuropathic Pain | 2026-12-30 |
| NCT06216886Stanford UniversityOnabotulinumtoxinA for Trigeminal Neuralgia | 2027-02-01 |
| NCT05269472University of MinnesotaTrigeminal Neuralgia Electrophysiology | 2027-11-01 |
| NCT05738096University of MinnesotaTrigeminal Evoked Responses to Improve Rhizotomy | 2027-11-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 34 studies in Trigeminal Neuralgia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to establish the validity of a patient reported diary in TN . The following objectives have been identified:
This study will engage up to 20 participants with TN through patient associations or HCPs. The study will be conducted in English Speaking countries.
The study comprises the following parts :
Adult patients or former patients with diagnosed trigeminal neuralgia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Validation of a pain diary specifically designed to capture pain dimensions of Trigeminal Neuralgia
Measure of pain associated with Trigeminal Neuralgia
Use of the TN Pain questionnaire to measure the pain associated with trigeminal neuralgia
Time frame: 2 weeks
Concept elicitation of the diary content
During an interview, assess if the questionnaire is comprehensive, clear and correctly captures patients experience
Time frame: 1 day
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2021 to primary completion in Aug 2023, 21 months.
Of 19 observational studies under Trigeminal Neuralgia, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Noema Pharma AG